AOP Orphan Pharmaceuticals Aktiengesellschaft
AOP Orphan Pharmaceuticals Aktiengesellschaft
Contact:
AOP
Phone: +43 503 72 44-24
E-Mail: olena.weissenbacher@aoporphan.com
KEYWORDS:
  • Jean-Guillaume Lecomte
  • AOP's neurology focus
  • Dr. Georg Fischer, AOP
  • narcolepsy
  • Dr. Rudolf Widmann
  • European Medicines Agency (EMA)
  • Wakix®
  • Bioprojet Pharma SAS
  • Wakix® (pitolisant)
  • AOP ORPHAN
Download Photos
AOP Orphan Pharmaceuticals Aktiengesellschaft (7 releases)

AOP Orphan and Bioprojet Pharma SAS entered a distribution agreement for Wakix®
* Bioprojet Pharma SAS and AOP Orphan Pharmaceuticals AG (AOP Orphan) entered a distribution agreement for Wakix®

AOP Orphan and Bioprojet Pharma SAS entered a distribution agreement for Wakix®
2018-03-22, pts20180322023 Products/Innovations, Science/Technology
AOP Orphan announces two-year results on Ropeginterferon alfa-2bin PV
2017-12-10, pts20171210001 Health/Medicine, Science/Technology
AOP Orphan Pharmaceuticals AG to acquire Selisistat
2017-10-02, pts20171002022 Products/Innovations, Health/Medicine
AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in PV
2017-06-25, pts20170625010 Products/Innovations, Health/Medicine
AOP Orphan starts EMA marketing authorization application procedure for Ropeginterferon alfa-2b
2017-03-14, pts20170314029 Health/Medicine, Products/Innovations
AOP Orphan announces European approvable opinion of its ultra-short acting beta blocker Rapibloc®
2016-07-11, pts20160711014 Health/Medicine, Products/Innovations